• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BTG helps fund immuno-oncology drug-device research programs

August 21, 2017 By Sarah Faulkner

BTGBTG (LON:BTG) and the Society of Interventional Oncology said today that it expanded its immuno-oncology/interventional oncology research grant program.

The group launched a second round of funding, designed help evaluate minimally invasive, image-guided therapies that use the body’s own immune system to treat cancer.

The program is specifically looking to fund proposals that assess how interventional oncologic therapies stimulate the immune system and how combination therapies can boost clinical outcomes. BTG and SIO also said they would consider applications that focus on understanding how loco-regional therapies shape adaptive and innate immunity in cancer patients.

In June, SIO announced the first round of grant recipients at the World Conference on Interventional Oncology in Boston. Those four proposals included both exploratory projects and prospective clinical trials.

“We are very pleased with the ongoing generosity of BTG that will continue to enable the SIO to fund additional meritorious, cutting-edge research that combines the strengths of interventional oncology and immuno-oncology — two disciplines that hold great promise for improving cancer therapy,” Dr. Nahum Goldberg, chair of the SIO interventional /immuno-oncology working group, said in prepared remarks.

“We were delighted by the number of high caliber entries we saw from investigators in response to the original call for proposals, with lots of brilliant ideas of how to best combine loco-regional and immunotherapies,” BTG chief scientific officer Melanie Lee added. “We believe such approaches can help new agents to penetrate solid tumour mass, expose tumour specific antigens, and help the immune system to mount a response. Given the high levels of interest, we have decided to double our efforts and provide further funding in 2018 to support additional research in this area.”

See the best minds in medtech live at DeviceTalks Boston on Oct. 2.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Imaging, Immunotherapy, Oncology, Pharmaceuticals, Research & Development Tagged With: BTG, societyofinterventionaloncology

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS